ADMA vs. NVO

Last updated Jun 9, 2026

ADMA (ADMA Biologics, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — ADMA in Biotechnology, NVO in Drug Manufacturers - General. Over the past 10 years, ADMA returned 1.08%/yr vs 6.20%/yr for NVO. At a 0.15 correlation, their price movements are largely independent.

Performance

ADMA vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADMA Biologics, Inc. (ADMA) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ADMA achieves a -55.81% return, which is significantly lower than NVO's -16.56% return. Over the past 10 years, ADMA has underperformed NVO with an annualized return of 1.08%, while NVO has yielded a comparatively higher 6.20% annualized return.

ADMA

• 1D: 1.13%
• 1M: -1.35%
• YTD: -55.81%
• 6M: -58.43%
• 1Y: -60.89%
• 3Y*: 28.26%
• 5Y*: 34.37%
• 10Y*: 1.08%

NVO

• 1D: -4.52%
• 1M: -10.96%
• YTD: -16.56%
• 6M: -9.23%
• 1Y: -42.47%
• 3Y*: -17.53%
• 5Y*: 1.78%
• 10Y*: 6.20%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ADMA vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ADMA ADMA Biologics, Inc.	-55.81%	6.36%	279.42%	16.49%	175.18%	-27.69%	-51.25%	67.36%	-25.55%	-37.30%
NVO Novo Nordisk A/S	-16.56%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Correlation

The correlation between ADMA and NVO is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.23
Correlation (5Y) Calculated over the trailing 5-year period	0.21
Correlation (10Y) Calculated over the trailing 10-year period	0.15
Correlation (All Time) Calculated using the full available price history since Oct 17, 2013	0.15

The correlation between ADMA and NVO shifts across timeframes, from 0.15 (all time) to 0.25 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap ADMA : $1.93B NVO : $182.49B
EPS ADMA : $0.68 NVO : $27.42
PE Ratio ADMA : 11.91 NVO : 1.50
PS Ratio ADMA : 3.86 NVO : 0.56
PB Ratio ADMA : 4.95 NVO : 0.90
Total Revenue (TTM) ADMA : $509.86M NVO : $327.80B
Gross Profit (TTM) ADMA : $312.42M NVO : $268.30B
EBITDA (TTM) ADMA : $218.74M NVO : $181.54B

Return for Risk

ADMA vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADMA

ADMA Risk / Return Rank: 3
ADMA Sharpe Ratio Rank: 3
ADMA Sortino Ratio Rank: 4
ADMA Omega Ratio Rank: 4
ADMA Calmar Ratio Rank: 5
ADMA Martin Ratio Rank: 2

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 9
NVO Sortino Ratio Rank: 12
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 13
NVO Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ADMA vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ADMA	NVO	Difference
Sharpe ratio: Return per unit of total volatility	-1.12	-0.82	-0.30
Sortino ratio: Return per unit of downside risk	-1.76	-1.01	-0.75
Omega ratio: Gain probability vs. loss probability	0.77	0.86	-0.09
Calmar ratio: Return relative to maximum drawdown	-0.94	-0.77	-0.16
Martin ratio: Return relative to average drawdown	-1.81	-1.14	-0.67
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ADMA vs. NVO - Sharpe Ratio Comparison

The current ADMA Sharpe Ratio is -1.12, which is lower than the NVO Sharpe Ratio of -0.82. The chart below compares the historical Sharpe Ratios of ADMA and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ADMA	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-1.12	-0.82	-0.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.58	0.05	+0.53
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.02	0.19	-0.18
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.47	-0.48

Drawdowns

ADMA vs. NVO - Drawdown Comparison

The maximum ADMA drawdown since its inception was -91.28%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for ADMA and NVO.

Drawdown Indicators

	ADMA	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-91.28%	-74.70%	-16.58%
Max Drawdown (1Y) Largest decline over 1 year	-65.25%	-55.03%	-10.22%
Max Drawdown (3Y) Largest decline over 3 years	-68.99%	-74.70%	+5.71%
Max Drawdown (5Y) Largest decline over 5 years	-68.99%	-74.70%	+5.71%
Max Drawdown (10Y) Largest decline over 10 years	-86.11%	-74.70%	-11.41%
Current Drawdown Current decline from peak	-67.12%	-70.19%	+3.07%
Average Drawdown Average peak-to-trough decline	-53.05%	-17.77%	-35.28%
Ulcer Index Depth and duration of drawdowns from previous peaks	33.62%	37.21%	-3.59%

Volatility

ADMA vs. NVO - Volatility Comparison

ADMA Biologics, Inc. (ADMA) has a higher volatility of 11.89% compared to Novo Nordisk A/S (NVO) at 9.75%. This indicates that ADMA's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ADMA	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.89%	9.75%	+2.14%
Volatility (6M) Calculated over the trailing 6-month period	45.36%	38.30%	+7.06%
Volatility (1Y) Calculated over the trailing 1-year period	54.73%	52.08%	+2.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.46%	38.31%	+21.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	69.05%	32.56%	+36.49%

Dividends

ADMA vs. NVO - Dividend Comparison

ADMA has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.39%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ADMA ADMA Biologics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.39%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Financials

ADMA vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between ADMA Biologics, Inc. and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.

Frequently Asked Questions

Can I hold both ADMA and NVO in my portfolio?

ADMA and NVO have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ADMA or NVO?

ADMA has higher volatility (11.89%) compared to NVO (9.75%). In terms of maximum drawdown, ADMA dropped -91.28% vs NVO's -74.70%.

Which has better risk-adjusted returns?

NVO currently has the higher Sharpe Ratio (-0.82 vs -1.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.